Compare Medpace Holdings Inc (MEDP) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Medpace Holdings Inc trades at $600.09 (market cap $16.90B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.28. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| MEDP | YMAG | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $620.59 | $15.98 |
52-Week Low | $393.42 | $10.76 |
Enterprise Value | $16.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
YMAG trades at $11.33, down 2.24% today, with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, with recent payments ranging from $0.07 to $0.40 per share. Technical indicators show strong trend momentum with ADX readings above 25, while RSI suggests potential overbought conditions on shorter timeframes.
YMAG's option income strategy generates substantial distributions but faces NAV stability challenges during earnings periods. The fund's structure effectively monetizes volatility in rangebound markets, though concentrated exposure to Magnificent Seven stocks creates single-sector risk. Current price action tests key support at $11-$12 resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
